Abrahamsen A F
Onkologisk avdeling, Det Norske Radiumhospital, Oslo.
Tidsskr Nor Laegeforen. 2000 Sep 10;120(21):2542-5.
The introduction of high dose chemotherapy of cancer has been followed by an increased incidence of therapy-related acute myeloid leukaemia and myelodysplastic syndrome.
A survey of the literature has shown that these complications have been attributed to a high accumulated dose of alkylating agents, antracyclins and epipodophyllotoxins. The incidence increases after additional irradiation.
After standard doses of leukaemogenic drugs the incidence of acute myeloid leukaemia and myelodysplastic syndrome is reported to be 0-4%, increasing to 8-10% after high dose therapy. At diagnosis of acute myeloid leukaemia and myelodysplastic syndrome, most of the patients have chromosomal abnormalities.
The prognosis of therapy-related acute myeloid leukaemia and myelodysplastic syndrome is poor compared to that in primary acute myeloid leukaemia and myelodysplastic syndrome.
癌症高剂量化疗应用后，与治疗相关的急性髓系白血病和骨髓增生异常综合征的发病率有所增加。
文献调查表明，这些并发症归因于烷化剂、蒽环类药物和表鬼臼毒素的高累积剂量。额外照射后发病率会增加。
据报道，使用标准剂量的致白血病药物后，急性髓系白血病和骨髓增生异常综合征的发病率为0 - 4%，高剂量治疗后增至8 - 10%。在诊断急性髓系白血病和骨髓增生异常综合征时，大多数患者存在染色体异常。
与原发性急性髓系白血病和骨髓增生异常综合征相比，与治疗相关的急性髓系白血病和骨髓增生异常综合征的预后较差。
